Inflammatory Bowel Disease Working Group

Dear Members

Membership and Governance

Members:
Rafeeq Muhammed (Chair: ibdchair@bspghan.org.uk)
Chris Spray (Secretary)
Jenny Epstein
David Devadason
Jochen Kammermeir
Mark Furman
Paul Henderson
Thankam Paul
Vijay Iyer
Naeem Ayub (Gastroenterology Council Member)
Michael Stanton (BAPS Representative)
Anne Willmott
Vacant (Trainee Rep)
Sibongile Chadokufa (Specialist Nurse Rep)
Janis Maginnis (Specialist Nurse Rep)

IBD Working Group 2017 Terms of Reference


IBD Service Standards 2008/2009. These have now been archived.

 


Opportunities to contribute to Cochrane reviews in IBD

Following-on from Morris’s presentation during the research session at the Annual Meeting in Leeds, the Cochrane IBD and Functional Bowel Disorder Group is actively looking to work with any and all BSPGHAN members in completing further systematic reviews in IBD. There are lots of ways that members can contribute – including those with no experience all the way through to those with active reviews who simply need some help. If you are interested please contact Morris Gordon mgordon@uclan.ac.uk


Very early onset IBD - produced by IBD Working Group


Azathioprine Safety Guidelines - produced by BSPGHAN IBD Working Group


Press Release Crohn’s and Colitis UK releases first Research Impact Report after awarding £5.2 million to research in the last 10 years

Press release Sept 2017 summarising the findings from the biologics audit. The National report is available to all via the RCP website if you want more details.


Article: Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey http://bmjopen.bmj.com/cgi/content/full/bmjopen-2017-016730?ijkey=egSqHfitRY84YGz&keytype=ref

Biosimilar statement from IBD Working Group: click here to read


Introducing biosimilar versions of Infliximab  NICE insights from the NHS  click here to view statement